IBDEI1DN ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24403,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24403,1,1,0)
 ;;=1^569.9
 ;;^UTILITY(U,$J,358.3,24403,1,2,0)
 ;;=2^INTESTINAL COND NEC
 ;;^UTILITY(U,$J,358.3,24403,2)
 ;;=^123842
 ;;^UTILITY(U,$J,358.3,24404,0)
 ;;=573.9^^136^1491^17
 ;;^UTILITY(U,$J,358.3,24404,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24404,1,1,0)
 ;;=1^573.9
 ;;^UTILITY(U,$J,358.3,24404,1,2,0)
 ;;=2^LIVER DISEASE NEC
 ;;^UTILITY(U,$J,358.3,24404,2)
 ;;=^123854
 ;;^UTILITY(U,$J,358.3,24405,0)
 ;;=580.9^^136^1492^1
 ;;^UTILITY(U,$J,358.3,24405,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24405,1,1,0)
 ;;=1^580.9
 ;;^UTILITY(U,$J,358.3,24405,1,2,0)
 ;;=2^ACUTE GLOMERULONEPHRITIS
 ;;^UTILITY(U,$J,358.3,24405,2)
 ;;=^270342
 ;;^UTILITY(U,$J,358.3,24406,0)
 ;;=584.9^^136^1492^2
 ;;^UTILITY(U,$J,358.3,24406,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24406,1,1,0)
 ;;=1^584.9
 ;;^UTILITY(U,$J,358.3,24406,1,2,0)
 ;;=2^ACUTE RENAL FAILURE
 ;;^UTILITY(U,$J,358.3,24406,2)
 ;;=^338532
 ;;^UTILITY(U,$J,358.3,24407,0)
 ;;=582.9^^136^1492^3
 ;;^UTILITY(U,$J,358.3,24407,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24407,1,1,0)
 ;;=1^582.9
 ;;^UTILITY(U,$J,358.3,24407,1,2,0)
 ;;=2^CHRONIC GLOMERULONEPHRITIS
 ;;^UTILITY(U,$J,358.3,24407,2)
 ;;=^270351
 ;;^UTILITY(U,$J,358.3,24408,0)
 ;;=585.9^^136^1492^4
 ;;^UTILITY(U,$J,358.3,24408,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24408,1,1,0)
 ;;=1^585.9
 ;;^UTILITY(U,$J,358.3,24408,1,2,0)
 ;;=2^CHRONIC KIDNEY DISEASE
 ;;^UTILITY(U,$J,358.3,24408,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,24409,0)
 ;;=586.^^136^1492^5
 ;;^UTILITY(U,$J,358.3,24409,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24409,1,1,0)
 ;;=1^586.
 ;;^UTILITY(U,$J,358.3,24409,1,2,0)
 ;;=2^RENAL FAILURE NEC
 ;;^UTILITY(U,$J,358.3,24409,2)
 ;;=^104733
 ;;^UTILITY(U,$J,358.3,24410,0)
 ;;=694.9^^136^1493^1
 ;;^UTILITY(U,$J,358.3,24410,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24410,1,1,0)
 ;;=1^694.9
 ;;^UTILITY(U,$J,358.3,24410,1,2,0)
 ;;=2^BULLOUS DERMATOSES NOS
 ;;^UTILITY(U,$J,358.3,24410,2)
 ;;=^187900
 ;;^UTILITY(U,$J,358.3,24411,0)
 ;;=695.10^^136^1493^2
 ;;^UTILITY(U,$J,358.3,24411,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24411,1,1,0)
 ;;=1^695.10
 ;;^UTILITY(U,$J,358.3,24411,1,2,0)
 ;;=2^ERYTHEMA MULTIFORME NOS
 ;;^UTILITY(U,$J,358.3,24411,2)
 ;;=^336759
 ;;^UTILITY(U,$J,358.3,24412,0)
 ;;=696.1^^136^1493^4
 ;;^UTILITY(U,$J,358.3,24412,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24412,1,1,0)
 ;;=1^696.1
 ;;^UTILITY(U,$J,358.3,24412,1,2,0)
 ;;=2^PSORIASIS
 ;;^UTILITY(U,$J,358.3,24412,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,24413,0)
 ;;=695.81^^136^1493^5
 ;;^UTILITY(U,$J,358.3,24413,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24413,1,1,0)
 ;;=1^695.81
 ;;^UTILITY(U,$J,358.3,24413,1,2,0)
 ;;=2^STAPHLYCOCCAL SCALED SKIN SYND
 ;;^UTILITY(U,$J,358.3,24413,2)
 ;;=^113858
 ;;^UTILITY(U,$J,358.3,24414,0)
 ;;=695.13^^136^1493^6
 ;;^UTILITY(U,$J,358.3,24414,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24414,1,1,0)
 ;;=1^695.13
 ;;^UTILITY(U,$J,358.3,24414,1,2,0)
 ;;=2^STEVENS-JOHNSON SYNDROME
 ;;^UTILITY(U,$J,358.3,24414,2)
 ;;=^336636
 ;;^UTILITY(U,$J,358.3,24415,0)
 ;;=695.15^^136^1493^7
 ;;^UTILITY(U,$J,358.3,24415,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24415,1,1,0)
 ;;=1^695.15
 ;;^UTILITY(U,$J,358.3,24415,1,2,0)
 ;;=2^TOXIC EPIDRML NECROLYSIS
 ;;^UTILITY(U,$J,358.3,24415,2)
 ;;=^336638
 ;;^UTILITY(U,$J,358.3,24416,0)
 ;;=695.9^^136^1493^3
 ;;^UTILITY(U,$J,358.3,24416,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24416,1,1,0)
 ;;=1^695.9
 ;;^UTILITY(U,$J,358.3,24416,1,2,0)
 ;;=2^ERYTHEMATOUS SKIN COND NEC
 ;;
 ;;$END ROU IBDEI1DN
